- Open Access
Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts: effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emission
© Christoph et al.; licensee BioMed Central Ltd. 2013
- Received: 29 October 2012
- Accepted: 17 January 2013
- Published: 23 January 2013
We investigated the utility of bioluminescence imaging (BLI) using firefly luciferase in monoclonal and polyclonal populations of leukemia cells in vitro and in vivo.
Monoclonal and polyclonal human lymphoid and myeloid leukemia cell lines transduced with firefly luciferase were used for BLI.
Kinetics and dynamics of bioluminescence signal were cell line dependent. Luciferase expression decreased significantly over time in polyclonal leukemia cells in vitro. Transplantation of polyclonal luciferase-tagged cells in mice resulted in inconsistent signal intensity. After selection of monoclonal cell populations, luciferase activity was stable, equal kinetic and dynamic of bioluminescence intensity and strong correlation between cell number and light emission in vitro were observed. We obtained an equal development of leukemia burden detected by luciferase activity in NOD-scid-gamma mice after transplantation of monoclonal populations.
The use of monoclonal leukemia cells selected for stable and equal luciferase activity is recommended for experiments in vitro and xenograft mouse models. The findings are highly significant for bioluminescence imaging focused on pre-clinical drug development.
- Bioluminescence imaging
- Monoclonal population
- Polyclonal population
- Firefly luciferase
Although animal models of leukemia often utilize survival time as the primary therapeutic end point, bioluminescence imaging (BLI) is increasingly being used to provide quantitative and more rapid assessment of drug efficacy in pre-clinical oncology research [1–5]. BLI of firefly luciferase activity provides a cost-effective and extremely sensitive method for imaging fundamental biological processes in vitro and in vivo[6–8]. In vivo BLI is an excellent method to gain a dynamic, longitudinal profile of engraftment . Luciferase oxidizes luciferin in the presence of adenosine tri-phosphate (ATP) and oxygen to form an electronically excited oxy-luciferin species. Visible light is emitted following the relaxation of excited oxy-luciferin to its ground state [10, 11]. Because this light can be transmitted through mammalian tissues, it is possible to use bioluminescence for non-invasive and quantitative monitoring of leukemia burden. However, the establishment of clinically relevant animal models that include sensitive detection of early cancer growth and leukemia burden remains an ongoing challenge in translational oncology research . Therefore, the difficulty in molecular imaging is in the development of effective imaging strategies with reporter systems that reveal cellular and molecular processes consistently throughout an entire study period [13–16]. Nevertheless, there are limitations associated with this approach. Using firefly luciferase as a reporter system requires exogenous luciferin addition and is currently not practical for large animal models. The rapid consumption of D-luciferin can potentially lead to an unstable signal . Further mammalian tissue is known to be a turbid medium that both scatters and absorbs photons. This is mostly due to changes in refractive index at cell membranes and internal organelles, and can lead to a scattered and attenuated bioluminescence signal, which has influence on investigations especially in deeper tissue . Bioluminescence imaging using firefly luciferase in vitro and in vivo is also often performed with potentially unstable luciferase-expressing polyclonal cell populations. In this study we investigated the limitations, advantages and disadvantages of bioluminescence imaging using a firefly luciferase system with monoclonal and polyclonal human leukemia cell populations in vitro and in a xenograft mouse model.
Instability and incomparability of luciferase activity in polyclonal human leukemia cell lines in vitro
Further, we observed a change in the kinetics of the bioluminescence signal in the leukemia cell lines (Jurkat, 697 and K562) after administration of D-luciferin. In all cell lines, the signal intensity increased to a maximum after injection of D-luciferin and then decreased slowly over time (Figure 1c, d). The kinetics of the bioluminescence signal were determined for the K562, 697 and Jurkat cell line eight days post-transduction and for the derivatives of the Jurkat cell line (wildtype, shControl and shMer) eighteen days post-transduction. The magnitude and timing of the maximum bioluminescence signal were cell line dependent. The maximum signal intensity was reached between 9 and 16 minutes after the administration of D-luciferin and was also cell line dependent (Figure 1c, d).
Finally, bioluminescence intensity decreased significantly in polyclonal luciferase-transduced leukemia cell lines over repeated passages (Figure 1e). The rate of luciferase signal decay was also cell line dependent, but all 3 cell lines exhibited significantly decreased signal intensity (>50%) within 3–4 weeks after transduction. The reduction was most dramatic in K562 cells, where bioluminescence intensity was decreased 80.4% at 25 days post transduction relative to the initial signal.
Inconsistent luciferase activity in a xenograft mouse model after transplantation of polyclonal leukemia cell lines
Stability and dynamics of luciferase activity in monoclonal human leukemia cell lines in vitro and in a xenograft mouse model
To the best of our knowledge, this study is the first reported investigation comparing bioluminescence imaging using a firefly luciferase system in monoclonal and polyclonal human leukemia cell populations in vitro and in a xenograft mouse model. We have shown that the bioluminescence signal intensity and the dynamics of luciferase activity in vitro were cell line dependent (Figure 1). Moreover, bioluminescence signal intensity was unstable in polyclonal populations and decreased significantly with repeated passage in culture. The decreasing signal observed may be due to survival and growth advantages for the non-transduced cells within the polyclonal cell population. We also observed dramatic variability in signal intensity in sub-lethally irradiated NSG mice transplanted with a polyclonal luciferase-transduced cell population, suggesting that in a polyclonal population, different clones contribute to establishment of disease in different mice (Figure 2). This source of heterogeneity significantly decreases the power of this model system to determine differences in disease progression related to experimental treatments. In addition, the variability in bioluminescence signal we observed in polyclonal luciferase-transduced populations limits side-by-side comparison of cell line derivatives with targeted genetic manipulations, where differences in signal intensity between cell lines will optimally be due solely to differences in disease progression, rather than cell line dependent differences in transduction efficiency and/or luciferase activity.
With the generation of monoclonal luciferase-expressing leukemia cell lines, stability of luciferase activity over a long period of time (> 4 months) was obtained. Comparable bioluminescence intensity in monoclonal luciferase-tagged cell lines with targeted genetic modifications was also observed. Moreover, monoclonal cell populations showed the same dynamic of bioluminescence intensity after administration of D-luciferin in vitro, revealing a significant advantage of this method (Figure 4). Most importantly, transplantation of monoclonal luciferase-transduced cell lines in a xenograft mouse model resulted in genetically and phenotypically identical disease with comparable disease kinetics, thereby significantly improving the utility and sensitivity of this model (Figure 5).
In the system used for our investigations, we demonstrated that the selection of monoclonal luciferase-expressing populations based on equal luciferase activity resulted in isolation of cell lines that were directly comparable, both in vitro and in vivo. Commonly the use of an antibiotic resistance marker would likely be sufficient for in vitro models. However, we avoided the treatment of leukemia cells with additional antibiotic agents to minimize putative in vivo drug interactions in future translational drug studies. In addition, antibiotic selected cell populations maintain a heterogeneous expression of luciferase, which may introduce variability to the transplanted cell population and may affect the consistency during the experiment.
The method to transplant monoclonal luciferase-transduced cell populations in murine xenograft models presented here has several advantages, but there are also some limitations which should be mentioned. First, we have seen that survival in xenograft models can be impacted by lentivirus transduction and/or luciferase expression in leukaemia cells and thus, these models may less accurately represent the normal biology of leukemogenesis (data not shown). Second, our data indicate that only monoclonal populations with the same growth characteristics, luciferase activity and phenotype can be directly compared in luciferase-based murine xenograft models, limiting the ease of their utility for comparison of genetically modified cell lines and their parental counterparts.
In conclusion, our data demonstrate that derivation of monoclonal cell lines is critical for development of robust, sensitive, and reproducible luciferase-based murine xenograft models. Non-invasive, longitudinal monitoring of leukemia progression in murine xenograft models based on bioluminescence intensity, as described here, will expedite the investigation and discovery of novel therapies. Using this methodology, direct comparison of leukemogenesis after targeted genetic modifications and sensitive, longitudinal determination of leukemia burden are both possible, thereby facilitating both target validation studies and robust testing of translational agents. Ultimately this approach may also prevent mischaracterization of therapies as ineffective based on unequal development of leukemia burden detected by bioluminescence intensity with the use of a polyclonal luciferase-expressing leukemia cell population.
Jurkat, 697 and K562 human leukemia cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA). All cell lines were cultured in RPMI-1640 medium (Hyclone Laboratories, Logan, UT) supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville, GA) and penicillin/streptomycin (100 units/ml and 100 μg/ml, Hyclone Laboratories, Logan, UT). Cells were maintained at 37°C in a humidified atmosphere containing 5% CO2. The identities of Jurkat, 697 and K562 cell lines were confirmed by short tandem repeat analysis and all cell cultures were determined to be free of mycoplasma contamination.
Lentivirus production and cell transduction
pCCL-MNDU3-LUC is a third generation HIV-1 based, lentiviral vector containing the firefly luciferase gene (gift from Yong-Mi Kim, Children’s Hospital Los Angeles, CA) . 293FT cells were transiently transfected with pCCL-MNDU3-LUC and a three-plasmid packaging system (Gag-Pol, Rev and VSV-G) using Turbofect (Fermentas, Glen Burnie, MD). Viral supernatants were harvested at 24 and 48 hours post-transfection and concentrated by ultracentrifugation. Jurkat wildtype, Jurkat shControl, Jurkat shMer1A, Jurkat shMer1B, 697 and K562 cells were transduced in the presence of polybrene (Millipore, Billerica, MA) and single cell sorting was performed using flow cytometry. Clonal populations were screened for luciferase activity by measurement of bioluminescence intensity as described below. Jurkat shControl, shMer1A, and shMer1B cell lines were generated using lentiviral shRNA vectors shMer1 (targeting Mer) and shControl (a non-silencing vector ) as previously described .
In vitro bioluminescence imaging
Actively growing human leukemia cells expressing luciferase were harvested from 10 cm2 tissue culture plates and viable cell counts were via trypan blue dye exclusion staining determined as the average of two counts using a hemocytometer. Serial dilutions of cells ranging from 1.25 × 105 to 1 × 106 cells per well were plated in 1 ml of medium in 24-well tissue culture plates. Untransfected human leukemia cells were plated in the same manner to determine auto-fluorescence for each population size. Wells containing medium only were used to detect background fluorescence. D-luciferin (Caliper Life Sciences, Hopkinton, MA) was added to a final concentration of 150 μg/ml immediately before bioluminescence imaging. Photon counts per second were recorded using an IVIS200 (Xenogen, Alameda, CA) imaging system and analyzed with Living Image 3.2 software (Caliper Life Sciences, Hopkinton, MA). Changes in bioluminescence intensity over time were measured and are presented as total flux values in photons/second for each well. Reported results are the average of three independent experiments.
Murine xenograft model
NOD scid gamma mice (NSG, Stock # 5557, The Jackson Laboratory, Bar Harbor, ME) were sub-lethally irradiated with 200 rads and intravenously transplanted with luciferase-expressing human leukemia cells (5 × 106 cells). Transplanted mice underwent in vivo bioluminescence imaging at various times as specified for each experiment. Animals were monitored daily and were euthanized upon signs of leukemia onset (weight loss >15%, decreased activity, and/or hind limb paralysis). All experiments involving animals followed the regulatory standards approved by the University of Colorado Institutional Animal Care and Use Committee.
In vivo bioluminescence imaging
NSG mice were anesthetized with inhaled isoflurane and were maintained with 1.5-2% isofluorane during imaging procedures. Luciferase-based bioluminescence imaging was performed with an IVIS200 imaging system equipped with a camera box and warming stage. Following intraperitoneal injection of 150 mg/kg D-luciferin dissolved in phosphate buffered saline (PBS), mice were immediately imaged with sequential 30, 60, 90 and 120 seconds exposures. Images were captured and bioluminescence intensity was quantitated using Living Image 3.2 acquisition and analysis software (Caliper Life Sciences, Hopkinton, MA). Total flux values were determined by drawing regions of interest (ROI) of identical size over each mouse and are presented in photons (p)/second (sec).
The mean bioluminescence intensities (photons/second) and corresponding standard errors were determined for each experiment. For all measurements, data are presented as mean ± standard error of the mean (SEM). The student’s t test was used to determine the significance of differences between means. The level of significance for all statistical analyses was chosen a priori to be p < 0.05. Statistical analyses were carried out using Prism software (Version 5.0, GraphPad Software, LaJolla, CA).
In vivo imaging was performed using the IVIS Shared Resource of the University of Colorado Cancer Center (supported by grant P30-CA046934). This work was supported in part by the National Institutes of Health (RO1CA137078 to DKG and F31CA157166 to FAC). DK Graham is a Damon Runyon-Novartis Clinical Investigator supported in part by the Damon Runyon Cancer Research Foundation (CI-39-07). The authors thank S. Robinson for critical reading of the article.
- Jenkins DE, Oei Y, Hornig YS, Yu SF, Dusich J, Purchio T, Contag PR: Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis. 2003, 20: 733-744.View ArticlePubMedGoogle Scholar
- Dothager RS, Flentie K, Moss B, Pan MH, Kesarwala A, Piwnica-Worms D: Advances in bioluminescence imaging of live animal models. Curr Opin Biotechnol. 2009, 20: 45-53. 10.1016/j.copbio.2009.01.007.PubMed CentralView ArticlePubMedGoogle Scholar
- Rehemtulla A, Stegman LD, Cardozo SJ, Gupta S, Hall DE, Contag CH, Ross BD: Rapid and Quantitative Assessment of Cancer Treatment Response Using In Vivo Bioluminescence Imaging. Neoplasia. 2000, 2: 491-495. 10.1038/sj.neo.7900121.PubMed CentralView ArticlePubMedGoogle Scholar
- Sweeney TJ, Mailänder V, Tucker AA, Olomu AB, Zhang W, Cao YA, Negrin RS, Contag CH: Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci U S A. 1999, 96: 12044-12049. 10.1073/pnas.96.21.12044.PubMed CentralView ArticlePubMedGoogle Scholar
- O'Neill K, Lyons SK, Gallagher WM, Curran KM, Byrne AT: Bioluminescent imaging: a critical tool in pre-clinical oncology research. J Pathol. 2010, 220: 317-327.PubMedGoogle Scholar
- Close DM, Hahn RE, Patterson SS, Baek SJ, Ripp SA, Sayler GS: Comparison of human optimized bacterial luciferase, firefly luciferase, and green fluorescent protein for continuous imaging of cell culture and animal models. J Biomed Opt. 2011, 16: 047003-1-047003-10.Google Scholar
- Choy G, O'Connor S, Diehn FE, Costouros N, Alexander HR, Choyke P, Libutti SK: Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging. Biotechniques. 2003, 35: 1022-1030.PubMedGoogle Scholar
- Kim JB, Urban K, Cochran E, Lee S, Ang A, Rice B, Bata A, Campbell K, Coffee R, Gorodinsky A, Lu Z, Zhou H, Kishimoto TK, Lassota P: Non-Invasive Detection of a Small Number of Bioluminescent Cancer Cells In Vivo. PLoS One. 2010, 5: e9364-10.1371/journal.pone.0009364.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang X, Rosol M, Ge S, Peterson D, McNamara G, Pollack H, Kohn DB, Nelson MD, Crooks GM: Dynamic tracking of human hematopoietic stem cell engraftment using in vivo bioluminescence imaging. Blood. 2003, 102: 3478-3482. 10.1182/blood-2003-05-1432.View ArticlePubMedGoogle Scholar
- Marques SM, Esteves da Silva JCG: Firefly bioluminescence: a mechanistic approach of luciferase catalyzed reactions. IUBMB Life. 2009, 61: 6-17. 10.1002/iub.134.View ArticlePubMedGoogle Scholar
- Nakatsu T, Ichiyama S, Hiratake J, Saldanha A, Kobashi N, Sakata K, Kato H: Structural basis for the spectral difference in luciferase bioluminescence. Nature. 2006, 440: 372-376. 10.1038/nature04542.View ArticlePubMedGoogle Scholar
- Inoue Y, Izawa K, Kiryu S, Kobayashi S, Tojo A, Ohtomo K: Bioluminescent evaluation of the therapeutic effects of total body irradiation in a murine hematological malignancy model. Exp Hematol. 2008, 36: 1634-1641. 10.1016/j.exphem.2008.08.004.View ArticlePubMedGoogle Scholar
- Inoue Y, Tojo A, Sekine R, Soda Y, Kobayashi S, Nomura A, Izawa K, Kitamura T, Okubo T, Ohtomo K: In vitro validation of bioluminescent monitoring of disease progression and therapeutic response in leukaemia model animals. Eur J Nucl Med Mol Imaging. 2006, 33: 557-565. 10.1007/s00259-005-0048-4.View ArticlePubMedGoogle Scholar
- Mezzanotte L, Fazzina R, Michelini E, Tonelli R, Pession A, Branchini B, Roda A: In vivo bioluminescence imaging of murine xenograft cancer models with a red-shifted thermostable luciferase. Mol Imaging Biol. 2010, 12: 406-414. 10.1007/s11307-009-0291-3.View ArticlePubMedGoogle Scholar
- Barrett DM, Seif AE, Carpenito C, Teachey DT, Fish JD, June CH, Grupp SA, Reid GSD: Non-invasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for pre-clinical modeling. Blood. 2011, 118: 112-117. 10.1182/blood-2011-04-346528.View ArticleGoogle Scholar
- Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS: Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood. 2003, 101: 640-648. 10.1182/blood-2002-06-1751.View ArticlePubMedGoogle Scholar
- Close DM, Xu T, Sayler GS, Ripp SA: In Vivo Bioluminescent Imaging (BLI): Noninvasive Visualization and Interrogation of Biological Processes in Living Animals. Sensors. 2011, 11: 180-206.PubMed CentralView ArticlePubMedGoogle Scholar
- Rice B, Cable M, Nelson MB: In vivo imaging of light-emitting probes. J Biomed Opt. 2001, 6: 432-440. 10.1117/1.1413210.View ArticlePubMedGoogle Scholar
- Park E, Gang EJ, Hsieh Y-T, Schaefer P, Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang E-S, Hoe Koo H, Hofmann W-K, Heisterkamp N, Pelus L, Keerthivasan G, Crispino J, Kahn M, Müschen M, Kim Y-M: Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood. 2011, 118: 2191-2199. 10.1182/blood-2011-04-351239.PubMed CentralView ArticlePubMedGoogle Scholar
- Migdall-Wilson J, Bates C, Schlegel J, Brandao L, Linger RM, DeRyckere D, Graham DK: Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus. PLoS One. 2012, 7: e31635-10.1371/journal.pone.0031635.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.